OWP Pharmaceuticals Announces Patent Application for the First-Ever Powder for Oral Liquid Formulation of Duloxetine Hydrochloride for the Treatment of Major Depressive and Generalized Anxiety Disorder
08 juil. 2020 08h00 HE
|
OWP Pharmaceuticals
NAPERVILLE, Ill., July 08, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting
29 mai 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
22 janv. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder
16 déc. 2019 06h00 HE
|
Axsome Therapeutics, Inc.
Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint) Statistically...
Nexstim Abp: Health Canada medicintekniska godkännande för Nexstim NBT® System
05 déc. 2019 04h10 HE
|
Nexstim Oyj
Företagsmeddelande, Helsingfors 5 december 2019 kl. 11.10 (EET) Nexstim Abp: Health Canada medicintekniska godkännande för Nexstim NBT® System Nexstim Abp (NXTMH:HEX, NXTMS:STO) meddelar att dess...
Nexstim Oyj: Kanadan terveysviranomainen on myöntänyt Nexstimin NBT®-laitteistolle lääkintälaitelisenssin
05 déc. 2019 04h10 HE
|
Nexstim Oyj
Yhtiötiedote, Helsinki, 5.12.2019 klo 11.10 Nexstim Oyj: Kanadan terveysviranomainen on myöntänyt Nexstimin NBT®-laitteistolle lääkintälaitelisenssin Nexstim Oyj (NXTMH:HEX, NXTMS:STO) ilmoittaa,...
Nexstim Plc: Health Canada Grants Nexstim NBT® Medical Device License for Canada
05 déc. 2019 04h10 HE
|
Nexstim Oyj
Company announcement, Helsinki, 5 December 2019 at 11.10 am (EET) Nexstim Plc: Health Canada Grants Nexstim NBT® Medical Device License for Canada Nexstim Plc (NXTMH:HEX, NXTMS:STO) announces that...
Axsome Therapeutics Announces Completion of Patient Enrollment in the GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
16 oct. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Nexstim Abp i teknologi licens förhandlingar med ett ledande akademiskt institut i Kalifornien
02 oct. 2019 02h00 HE
|
Nexstim Oyj
Pressmeddelande, Helsingfors, 2 oktober 2019 kl 9.00 (EEST) Nexstim Abp i teknologi licens förhandlingar med ett ledande akademiskt institut i Kalifornien Nexstim Abp (NXTMH:HEX, NXTMS:STO)...
Nexstim Oyj neuvottelee teknologialisenssistä johtavan kalifornialaisen akateemisen instituutin kanssa
02 oct. 2019 02h00 HE
|
Nexstim Oyj
Yhtiötiedote, Helsinki, 2.10.2019 klo 9.00 (EEST) Nexstim Oyj neuvottelee teknologialisenssistä johtavan kalifornialaisen akateemisen instituutin kanssa Nexstim Oyj (NXTMH:HEX, NXTMS:STO) (”Nexstim”...